These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 31268584)

  • 1. Pathogen reduced plasma products: a clinical practice scientific review from the AABB.
    Cushing MM; Pagano MB; Jacobson J; Schwartz J; Grossman BJ; Kleinman S; Han MA; Cohn CS;
    Transfusion; 2019 Sep; 59(9):2974-2988. PubMed ID: 31268584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward universal pathogen reduction of the blood supply (Conference Report, p. 3002).
    Marks P; Verdun N
    Transfusion; 2019 Sep; 59(9):3026-3028. PubMed ID: 31218709
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).
    Atreya C; Glynn S; Busch M; Kleinman S; Snyder E; Rutter S; AuBuchon J; Flegel W; Reeve D; Devine D; Cohn C; Custer B; Goodrich R; Benjamin RJ; Razatos A; Cancelas J; Wagner S; Maclean M; Gelderman M; Cap A; Ness P
    Transfusion; 2019 Sep; 59(9):3002-3025. PubMed ID: 31144334
    [No Abstract]   [Full Text] [Related]  

  • 4. [Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
    Cazenave JP
    Bull Acad Natl Med; 2010 Dec; 194(9):1707-19; discussion 1719-20. PubMed ID: 22043595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Component pathogen inactivation: a critical review.
    Prowse CV
    Vox Sang; 2013 Apr; 104(3):183-99. PubMed ID: 23134556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
    Di Minno G; Navarro D; Perno CF; Canaro M; Gürtler L; Ironside JW; Eichler H; Tiede A
    Ann Hematol; 2017 Aug; 96(8):1253-1270. PubMed ID: 28624906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects.
    Irsch J; Seghatchian J
    Transfus Apher Sci; 2015 Apr; 52(2):240-4. PubMed ID: 25824703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion of pathogen-reduced platelet components without leukoreduction.
    Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
    Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of bacterial risk: pathogen inactivation/detection of bacteria].
    Morel P; Naegelen C; Deschaseaux M; Bardiaux L
    Transfus Clin Biol; 2013 May; 20(2):109-14. PubMed ID: 23622837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
    Klamroth R; Gröner A; Simon TL
    Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.
    Cicchetti A; Berrino A; Casini M; Codella P; Facco G; Fiore A; Marano G; Marchetti M; Midolo E; Minacori R; Refolo P; Romano F; Ruggeri M; Sacchini D; Spagnolo AG; Urbina I; Vaglio S; Grazzini G; Liumbruno GM
    Blood Transfus; 2016 Jul; 14(4):287-386. PubMed ID: 27403740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusion-associated circulatory overload risk mitigation: survey on hospital policies for compliance with AABB Standard 5.9.17.
    Yazer MH; Dunbar NM; Thomas J; Nunes E; Murphy MF;
    Transfusion; 2019 Sep; 59(9):2833-2839. PubMed ID: 31393616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Techniques of preparation and indications of labile blood products].
    Clément S
    Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the use of pathogen-reduced human plasma and platelet concentrates.
    Seltsam A; Müller TH
    Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk.
    Devine DV; Schubert P
    Hematol Oncol Clin North Am; 2016 Jun; 30(3):609-17. PubMed ID: 27112999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogen inactivation of platelet concentrates and fresh frozen plasma.
    Jackson JE
    Br J Biomed Sci; 2003; 60(4):227-32. PubMed ID: 14725341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The status of pathogen-reduced plasma.
    Sandler SG
    Transfus Apher Sci; 2010 Dec; 43(3):393-399. PubMed ID: 20932804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.